Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $33.28 USD
Change Today -0.63 / -1.86%
Volume 469.4K
ACOR On Other Exchanges
Symbol
Exchange
Berlin
As of 8:10 PM 03/31/15 All times are local (Market data is delayed by at least 15 minutes).

acorda therapeutics inc (ACOR) Key Developments

Acorda Therapeutics, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 11:00 AM

Acorda Therapeutics, Inc. Presents at RBC Capital Markets Healthcare Conference 2015, Feb-24-2015 11:00 AM. Venue: The New York Palace Hotel, New York, New York, United States. Speakers: Ron Cohen, Founder, Chief Executive Officer, President and Director.

Acorda Therapeutics, Inc. Announces Unaudited Consolidated Financial Results for the Fourth Quarter and Full Year Ended December 31, 2014; Reports Asset Impairment for the Fourth Quarter Ended December 31, 2014

Acorda Therapeutics, Inc. announced unaudited consolidated financial results for the fourth quarter and full year ended December 31, 2014. For the quarter, the company reported net income of $0.3 million, or $0.01 per diluted share against net income in the same quarter of 2013 was $6.2 million, or $0.15 per diluted share a year ago. Non-GAAP net income was $19.7 million, or $0.46 per diluted share against non-GAAP net income of $18.9 million, or $0.45 per diluted share a year ago. Total Revenue was $117.872 million against $92.593 million a year ago. Operating income was $1.169 million against $12.749 million a year ago. Loss before income taxes was $2.693 million compared to income before income taxes of $12.630 million a year ago. For the full year, the company reported net income of $17.7 million, or $0.42 per diluted share against net income for the full year 2013 was $16.4 million, or $0.39 per diluted share a year ago. Non-GAAP net income was $73.8 million, or $1.74 per diluted share against non-GAAP net income for the full year ended December 31, 2013 of $52.4 million, or $1.26 per diluted share. Total revenues were $401.480 million against $336.430 million a year ago. Operating income was $36.391 million against $30.365 million a year ago. Income before income taxes was $28.009 million compared to $28.863 million a year ago. For the fourth quarter ended December 31, 2014. the company reported asset impairment of $6.991 million.

Acorda Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 01:35 PM

Acorda Therapeutics, Inc. Presents at Barclays Global Healthcare Conference, Mar-11-2015 01:35 PM. Venue: Loews Miami Beach Hotel, 1601 Collins Avenue, Miami, Florida, United States. Speakers: Michael W. Rogers, Chief Financial Officer and Principal Accounting Officer.

Acorda Therapeutics, Inc., Q4 2014 Earnings Call, Feb 12, 2015

Acorda Therapeutics, Inc., Q4 2014 Earnings Call, Feb 12, 2015

Acorda Announces Safety and Tolerability Data from First Clinical Trial of Remyelinating Antibody in Multiple Sclerosis

Acorda Therapeutics, Inc. announced safety and tolerability data from a Phase 1 clinical trial of rHIgM22, a remyelinating antibody being studied for the treatment of multiple sclerosis (MS). The trial, which followed participants for up to six months after receiving a single dose of rHIgM22, found no dose-limiting toxicities at any of the five dose levels studied. Based on these data, the Company intends to advance clinical development of rHIgM22. This was a multi-center, double-blind, randomized, placebo-controlled study designed to evaluate safety, tolerability, pharmacokinetics, and immunogenicity of a single dose of rHIgM22 in participants with any type of MS who were clinically stable for at least three months. All participants remained on their existing MS treatment regimens, including disease-modifying therapies. The first part of the study included five cohorts, with each cohort receiving a higher dose of rHIgM22 than the previous one. Each cohort consisted of 10 participants (eight receiving drug, two receiving placebo), who were followed for three months after receiving a single dose of study medication. In the second part of the study, 21 treatment-na -ve participants were randomized to receive placebo or one of the two high doses of rHIgM22 from the first part of the study. These participants were followed for six months to assess safety and tolerability. The second part of the study also included several exploratory clinical, imaging and biomarker measures, which are still being analyzed. The study was not powered to determine statistical significance on these measures.

 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
ACOR:US $33.28 USD -0.63

ACOR Competitors

Market data is delayed at least 15 minutes.

Company Last Change
ACADIA Pharmaceuticals Inc $32.59 USD -0.76
Biogen Inc $422.24 USD -9.38
Depomed Inc $22.41 USD -0.42
Durect Corp $1.91 USD -0.09
Isis Pharmaceuticals Inc $63.67 USD -1.14
View Industry Companies
 

Industry Analysis

ACOR

Industry Average

Valuation ACOR Industry Range
Price/Earnings 81.6x
Price/Sales 3.5x
Price/Book 2.6x
Price/Cash Flow 81.7x
TEV/Sales 2.1x
 | 

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact ACORDA THERAPEUTICS INC, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.